ArticleVaccine2012
The economic value of a quadrivalent versus trivalent influenza vaccine.
Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05494047 (A Phase III, Randomized, Double-blind and Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Influenza Vaccine, Inactivated, Quadrivalent Developed by Sinovac Biotech Co., Ltd. Compared to a Licensed Quadrivalent Influenza Vaccine, VaxigripTetra™, in Individuals Aged 3 Years and Older in Chile), which is not on this map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized, Double-blind and Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Influenza Vaccine, Inactivated, Quadrivalent Developed by Sinovac Biotech Co., Ltd. Compared to a Licensed Quadrivalent Influenza Vaccine, VaxigripTetra™, in Individuals Aged 3 Years and Older in Chile
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023Pooled it
- The Value(s) of Vaccination: Building the Scientific Evidence According to a Value-Based Healthcare Approach.Frontiers in public health · 2022Pooled it
- Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer.PharmacoEconomics · 2016Pooled it
- Assessment of Immunogenicity of Adjuvanted Quadrivalent Inactivated Influenza Vaccine in Healthy People and Patients With Common Variable Immune Deficiency.Frontiers in immunology · 2020Trial
- Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study.Human vaccines & immunotherapeutics · 2016Trial
- Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.BMC infectious diseases · 2013Trial
- Fighting the flu in the tropics: The role of influenza vaccination in Southeast Asia.Asia Pacific allergy · 2025Article
- Streptococcus pneumoniae and influenza vaccination rates in oncological patients - data from Germany.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- [Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax TetraJournal of preventive medicine and hygiene · 2022Article
- Review
- Review
- Influenza vaccination: protecting the most vulnerable.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Quadrivalent cell culture influenza virus vaccine. Comparison to egg-derived vaccine.Human vaccines & immunotherapeutics · 2020Article
- Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines.Antimicrobial resistance and infection control · 2019Article
- Review
- Vaccination programs for older adults in an era of demographic change.European geriatric medicine · 2018Review
- Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.Human vaccines & immunotherapeutics · 2017Article
- Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America.Human vaccines & immunotherapeutics · 2017Article
- Epidemiology of influenza B in Australia: 2001-2014 influenza seasons.Influenza and other respiratory viruses · 2017Article
- A systems approach to vaccine decision making.Vaccine · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The recently licensed quadrivalent seasonal influenza vaccine (QIV) may provide better protection than the traditional trivalent influenza vaccine (TIV) as it includes one more influenza B strain. We developed a Monte Carlo simulation model to determine the economic value of a QIV compared to the TIV for 10 influenza seasons (1999-2009). The addition of the influenza B strain to convert the TIV into a QIV could result in substantial cost-savings to society (median of $3.1 billion) and third party payers (median of $292 million), even when the cost of QIV is significantly higher.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.